Product Pipeline

Therapeutics
Pre-clin
Phase 1
Phase 2
Phase 3
NDA/BLA
Phase
Ryplazim®
Congenital Deficiency
Fezagepras (PBI-4050)
Additional Multiple Ascending Dose (MAD) Study
Fezagepras (PBI-4050)
Liver Fibrotic Diseases e.g. NASH
Fezagepras (PBI-4050)
Lung Fibrotic Diseases e.g. Idiopathic Pulmonary Fibrosis (IPF)
Fezagepras (PBI-4050)
Kidney Fibrotic Diseases e.g. Chronic Kidney Disease (CKD)
Fezagepras (PBI-4050)
Alström Syndrome
Selective GPR84 Antagonist
Fibrosis
Selective OXER1 Antagonist
Respiratory/GI